LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that an experimental animal trial produced statistically significant evidence that the company’s chaperone amplifying drug candidate arimoclomol provided protection from the detrimental cognitive and sensorimotor effects of low atmospheric oxygen (hypoxia) that occurs at high altitudes. Data from this trial will be presented in a poster, “A heat-shock protein co-inducer treatment improves behavioral performance in rats exposed to hypoxia,” on July 9 at the 37th Annual International Society on Oxygen Transport to Tissue (ISOTT) Conference, being held in Cleveland, Ohio.
